Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lapatinib

lapatinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of lapatinib

48 trials tracked of lapatinib: 14 in phase 3 or 4 and 4 with published results. The most-cited published study has 610 citations.

48Trials tracked
14Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 13 Phase 2 30 Phase 1 4
  1. Phase 3 A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting Completed · 610 cited
  2. Phase 3 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Completed · 352 cited
  3. Phase 3 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Completed · 166 cited
  4. Phase 4 A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval Completed · 3 cited
  5. Phase 3 Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer Completed
  6. Phase 3 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed
Show 42 more trials
  1. Phase 3 Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer Completed
  2. Phase 3 Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer Completed
  3. Phase 3 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Completed
  4. Phase 3 Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Completed
  5. Phase 3 Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study Completed
  6. Phase 3 A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer Completed
  7. Phase 3 Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer Completed
  8. Phase 3 ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D Completed
  9. Phase 2 Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer Completed
  10. Phase 2 Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer Completed
  11. Phase 2 Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer Completed
  12. Phase 2 Lapatinib in Combination With Vinorelbine Completed
  13. Phase 2 Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma Completed
  14. Phase 2 Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel Completed
  15. Phase 2 Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients Completed
  16. Phase 2 Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer Completed
  17. Phase 2 Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin Completed
  18. Phase 2 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed
  19. Phase 2 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab Completed
  20. Phase 2 Lapatinib and Bevacizumab for Metastatic Breast Cancer Completed
  21. Phase 2 Neoadjuvant GW572016 to Treat Breast Cancer Completed
  22. Phase 2 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Completed
  23. Phase 2 Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer Completed
  24. Phase 2 Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer Completed
  25. Phase 2 Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery Completed
  26. Phase 2 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed
  27. Phase 2 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Completed
  28. Phase 2 Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer Completed
  29. Phase 2 TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. Completed
  30. Phase 2 Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer Completed
  31. Phase 2 Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. Completed
  32. Phase 2 Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer Completed
  33. Phase 2 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed
  34. Phase 2 Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer Completed
  35. Phase 2 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Completed
  36. Phase 2 GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer Completed
  37. Phase 2 Lapatinib and Trastuzumab With or Without Endocrine Therapy Completed
  38. Phase 2 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma Completed
  39. Phase 1 Concentration and Activity of Lapatinib in Vestibular Schwannomas Completed
  40. Phase 1 Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer Completed
  41. Phase 1 Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer Completed
  42. Phase 1 LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients Completed

Showing the 48 most-cited and recently-updated of 48 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
DeSTIL-positive HER2+ breast cancer patients show HR 0.09 for event-free survival with trastuzumab
Oncology RCT
DeSTIL-positive HER2+ breast cancer patients show HR 0.09 for event-free survival with trastuzumab Trial Shows DeSTIL Signature Identifies Patients Benefiting From Trastuzumab
This Phase III randomized clinical trial evaluated the DeSTIL signature in a cohort of 221 validation patients and 250 training patients wit…
A new genetic marker called DeSTIL helps identify which HER2-positive breast cancer patients may see better outcomes when treated with trast…
Jun 18, 2026
Phase II trial tests induction chemo with carboplatin, paclitaxel, lapatinib before transoral surgery in SCCHN
OB/GYN & Women's Health Phase II
Phase II trial tests induction chemo with carboplatin, paclitaxel, lapatinib before transoral surgery in SCCHN Can a gentler, three-part treatment plan reduce side effects for head and neck cancer?
A single-arm phase II trial enrolled 40 previously untreated patients with SCCHN amenable to transoral surgery.
A three-part treatment plan for head and neck cancer aims to reduce harsh side effects by tailoring care based on surgery results.
CT.gov Mar 30, 2026